Unity Biotechnology, Inc.

NasdaqGS UBX

Unity Biotechnology, Inc. Total Assets for the quarter ending September 30, 2024

Unity Biotechnology, Inc. Total Assets is NA for the quarter ending September 30, 2024. Total assets are the total value of all assets owned by a company, representing its resources.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGS: UBX

Unity Biotechnology, Inc.

CEO	Dr. Anirvan Ghosh Ph.D.
IPO Date	May 3, 2018
Location	United States
Headquarters	285 East Grand Avenue
Employees	19
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Key trends

Past 5 years